

# TABLE OF CONTENTS

November 16, 2009

No. 2164

## BUSINESS

- 1 Quintiles Is More Than a CRO: Dr Winstanly  
- Quintiles Allies with AZ for Extensive Clinical Pharmacology Studies
- 2 Eisai Reshuffles R&D System to Speed Up Development of Anticancer Drugs  
- E7389 Prolongs OS in Breast Cancer
- 3 Strong Yen Hit Top-Eight Domestic Companies' Performance  
- Growth Also Decelerates in Domestic Market
- 4 Half-Year Business Results of Domestic Companies: 2  
- Astellas: Good Sales of Vesicare Make Up for Negative Effects of the Strong Yen  
- Shionogi: Sales Up 26.3% with Addition of Sciele  
- Ono: New Products Buttress Sales  
- Kaken: Sales Up 3.0% Driven by Strong Sales of Main Products  
- Mochida: 3 Main Products Drive Sales Up 5.2%  
- Torii: New Products Drive Sales  
- ASKA: Losses Due to Slump of Mainstay Products  
- Nippon Chemiphar: Sales of Generics Up 24%  
- JCR Pharmaceuticals: Sales Up 16.6% Driven by Growject  
- Wakamoto: Operating Losses due to Slump of Mainstay Products  
- Asahi Kasei Pharma: Sales Down 14.4%  
- Teijin Pharma: Drugs for Osteoporosis Prop Up Overall Business
- 9 Olmetec Acquires 3rd-Largest Share in ARB Market in Japan  
- Global Sales of US\$22.6 Mil. in 3rd Qtr
- 10 DSP Hurries to Build Up Its Own Marketing System for Lurasidone  
- DSP Creates International Business Division to Promote US Operations
- 10 Kyorin License Neramexane for Tinnitus from Merz
- 11 Banyu to Boost Its Vaccine Business with Pneumovax, Gardasil  
- Pneumococcal Vaccine Pneumovax in Short Supply
- 12 GSK to Promote Cervarix Targeting All Dept. and Deploying over 1,000 MRs
- 12 Medipal to Further Drug Distribution System Reform  
- Operating Profits Down 13.5%
- 13 Alfresa to Begin Business in China in Earnest  
- Sales Up 7% due to Addition of New Customers

## REGULATORY

- 14 Big Changes in Style of Discussions at *Chuikyo*

- 14 Pricing Rule to Be Revised for New Products Containing Existing API: *Chuikyo*
- 15 Share of Original Drugs Not Decreasing Much in Japan Despite Large Fall in Prices: *Koroshō* Survey
- 15 *Koroshō* Considers Revising Medical Fees to Induce Doctors to Prescribe Fewer Antipsychotics
- 16 Deeply Cut Prices of New Drugs to Save Failing Healthcare System: *Hodanren*  
- *Koroshō* Reconfirms Intention to Draw a Conclusion on Industry's Proposal by Year-End
- 16 **REGULATORY NEWS IN BRIEF**  
- Shionogi Applies for Peramivir in Japan  
- Celgene Submits 2nd Application for Lenalidomide in Japan  
- Arzerra Receives Accelerated Approval by FDA: GSK, Genmab  
- Micardis for CV Morbidity Receives Positive Opinion from CHMP: BI

## COMMENTARY

- 18 **Maurer's Healthcare Insight (115)**  
- Japan Pharma Industry Reform: P. Reed Maurer

## R&D

- 20 Takeda Ties Up with Amylin for Obesity Treatment
- 20 **R&D NEWS IN BRIEF**  
- Daiichi Sankyo Initiates PIII Trial for CS-8958  
- Shionogi Discontinues Negotiations for S-2367  
- Epadel Reduces Coronary Events in Sugar Metabolism Disorders  
- New Data Show Safety of SC Administration of Orencia: BMS  
- Tasigna More Effective Than Gilvec for Ph+ CML: Novartis

## TOPICS

- 21 Pfizer Starts Shipment of New Norvasc OD Tablets
- 23 InCROM to Conduct Mock PI Trials for Drug Makers' Employees

## GENERICS

- 22 Cut Prices of Off-Patent Original Drugs before Calling for Use of Generics: TMA
- 22 Premium Prices Needed for Biosimilars: Mr Nagano at *Chuikyo*

## MEDICAL DEVICES

- 23 **MEDICAL DEVICE NEWS IN BRIEF**  
- Asahi Kasei Kuraray Medical's South Korean Subsidiary Starts Operation  
- Hospira Japan Launches GemStar PCA Pump